Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F21%3A00123257" target="_blank" >RIV/00216224:14110/21:00123257 - isvavai.cz</a>

Result on the web

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12456" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12456</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jebm.12456" target="_blank" >10.1111/jebm.12456</a>

Result language

angličtina

Original language name

Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data

Original language description

Proton pump inhibitors (PPIs) were first introduced in the market in the 1980s and are used as an over-the-counter (OTC) drug for acid-related diseases of the gastrointestinal tract. (1) Over the years, both prescription and non-prescription use of PPIs has grown exponentially, and they are now among the most widely used class of drugs globally. (2) PPIs are generally intended for short-term use and are rarely required beyond four to eight weeks; however, in real-world practice, their duration of use often extends beyond recommended guidelines. Hepatocellular carcinoma (HCC), a primary liver cancer, is a heterogeneous disease with multiple variables that differ by geography and presence or absence of prognostic factors such as NAFLD and cirrhosis. Preclinical studies have found PPIs-induced acid suppression to be associated with disease progression in hepatic diseases such as alcoholic liver disease, NAFLD, non-alcoholic steatohepatitis, and liver tumors. Similarly, population-based studies have also found an association of PPIs use with the risk of acute liver injury. (3) Nevertheless, many recent pharmacoepidemiologic studies using real-world databases to evaluate the association between PPIs and the risk of HCC show divergent results. (4-6) Thus, a systematic review was conducted to identify all the published articles and to determine the effect of PPI on the risk of HCC based on real-world data studies.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30218 - General and internal medicine

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

JOURNAL OF EVIDENCE BASED MEDICINE

ISSN

1756-5383

e-ISSN

1756-5391

Volume of the periodical

14

Issue of the periodical within the volume

4

Country of publishing house

US - UNITED STATES

Number of pages

3

Pages from-to

278-280

UT code for WoS article

000706758800001

EID of the result in the Scopus database

2-s2.0-85116877084